Promising Gene therapy Restoring Vision
Gene therapy currently is one of the most promising treatments for genetic blindness. Humans rely dominantly on their eyesight. Losing vision means not being able to read, recognize faces, or find objects. Several common eye diseases damage the retina, the light-sensitive tissue in the back of the eye. Cells in the retina called photoreceptors convert light into signals sent to the brain.
Macular degeneration is one of the major reasons for visual impairment, round the globe, close to 200 million people are affected. Age-related macular degeneration and retinitis pigmentosa are among the diseases that damage photoreceptors, leading to vision loss. Photoreceptors in the retina are responsible to capture the light coming from the environment through the eye. There is no cure for these diseases. Interventions have been aimed at slowing retinal degeneration. Implantable devices called retinal prostheses can restore limited vision for some.
“During the progression of degenerative photoreceptor diseases, light-sensitive and light-insensitive photoreceptor regions in the retina coexist. For example, macular degeneration patients lose vision in the central portion of their retina but retain peripheral eyesight.”
Researchers have been developing gene therapy approaches that bypass damaged photoreceptors to restore sight. They use a harmless virus to deliver a gene that allows remaining retinal cells to produce a protein enabling them to sense light. Diseased photoreceptors lose their sensitivity to light, which can lead to impaired vision or even complete blindness. Scientists of the Institute of Molecular and Clinical Ophthalmology Basel (IOB) together with colleagues from the German Primate Center (DPZ) – Leibniz Institute for Primate Research in Göttingen have developed a completely new therapeutic approach based on gene therapy.
Current treatments use light-sensitive proteins called opsins, which are normally made by the rod and cone photoreceptors in the retina. The main cause of blindness in industrialized countries is the degeneration of photoreceptors, including age-related macular degeneration and retinitis pigmentosa. During the progression of degenerative photoreceptor diseases, light-sensitive and light-insensitive photoreceptor regions in the retina coexist. For example, macular degeneration patients lose vision in the central portion of their retina but retain peripheral eyesight.
Scientists have now succeeded in developing a new therapeutic approach to restore light sensitivity in degenerating retina without negatively affecting remaining vision. They were inspired by species found in nature, such as bats and snakes, that can localize near-infrared light emitted by the bodies of their prey. This is done by using heat-sensitive ion channels that are able to detect the heat of the near-infrared light. This enables the bats and snakes to superimpose thermal and visual images in the brain and thus react to their environment with greater precision.
To equip retinal photoreceptors with near-infrared sensitivity, the researchers devised a three-component system. The first component contains engineered DNA that ensures that the gene coding for the heat-sensitive channel is only expressed in photoreceptors. The second component is a gold nanorod, a small particle, that efficiently absorbs near-infrared light. The third component is an antibody that ensures strong binding between the heat-sensitive channel expressed in photoreceptors and the gold nanorods that locally capture near-infrared light and locally release heat.
The researchers first tested their system in engineered mice with retinal degeneration, confirming that near-infrared light effectively excites photoreceptors and that this signal is transmitted to retinal ganglion cells, the latter representing the output of the retina towards higher visual centers in the brain. Next, they showed that stimulating the mouse eye with near-infrared light is also picked up by neurons in a brain area that is important for conscious vision, the primary visual cortex. They also designed a behavioral test in which untreated blind mice were not able to use near-infrared stimulation to learn a simple task whereas blind mice treated with the three-component system could perform the task related to the near-infrared stimulus. Experimental results showed that following treatment with the three-component gene therapy method, near-infrared light exposures reactivated the human retina’s visual circuitry.
“We believe that near-infrared stimulation is an important step towards providing a useful vision to blind patients so that they can regain their ability to read or see faces”, says Daniel Hillier, head of the junior research group Visual Circuits and Repair at DPZ, and adds: “We want to give hope to blind people with these findings and will further intensify our research activities in this area here at DPZ within our main project, which focuses on the restoration of vision.”